Β2 Adrenergic Agonist Suppresses Eosinophil-Induced Epithelial-To- Mesenchymal Transition of Bronchial Epithelial Cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N

Total Page:16

File Type:pdf, Size:1020Kb

Β2 Adrenergic Agonist Suppresses Eosinophil-Induced Epithelial-To- Mesenchymal Transition of Bronchial Epithelial Cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N Kainuma et al. Respiratory Research (2017) 18:79 DOI 10.1186/s12931-017-0563-4 RESEARCH Open Access β2 adrenergic agonist suppresses eosinophil-induced epithelial-to- mesenchymal transition of bronchial epithelial cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N. D’Alessandro-Gabazza2, Masaaki Toda2, Taro Yasuma2, Kota Nishihama2, Hajime Fujimoto3, Yu Kuwabara1,2, Koa Hosoki1,2, Mizuho Nagao1, Takao Fujisawa1 and Esteban C. Gabazza2* Abstract Background: Epithelial-mesenchymal transition is currently recognized as an important mechanism for the increased number of myofibroblasts in cancer and fibrotic diseases. We have already reported that epithelial- mesenchymal transition is involved in airway remodeling induced by eosinophils. Procaterol is a selective and full β2 adrenergic agonist that is used as a rescue of asthmatic attack inhaler form and orally as a controller. In this study, we evaluated whether procaterol can suppress epithelial-mesenchymal transition of airway epithelial cells induced by eosinophils. Methods: Epithelial-mesenchymal transition was assessed using a co-culture system of human bronchial epithelial cells and primary human eosinophils or an eosinophilic leukemia cell line. Results: Procaterol significantly inhibited co-culture associated morphological changes of bronchial epithelial cells, decreased the expression of vimentin, and increased the expression of E-cadherin compared to control. Butoxamine, a specific β2-adrenergic antagonist, significantly blocked changes induced by procaterol. In addition, procaterol inhibited the expression of adhesion molecules induced during the interaction between eosinophils and bronchial epithelial cells, suggesting the involvement of adhesion molecules in the process of epithelial-mesenchymal transition. Forskolin, a cyclic adenosine monophosphate-promoting agent, exhibits similar inhibitory activity of procaterol. Conclusions: Overall, these observations support the beneficial effect of procaterol on airway remodeling frequently associated with chronic obstructive pulmonary diseases. Keywords: Asthma, Eosinophils, Epithelial cells, Integrins Background the first line drug for relief of acute asthma symptoms but Obstructive pulmonary diseases such as bronchial asthma a long-term controller in combination with inhaled corti- and chronic obstructive pulmonary disease are chronic in- costeroids. Procaterol is a selective and full β2 adrenergic flammation of the airways that are frequently associated agonist that is used as a rescue of asthmatic attack in with lung structural changes, termed airway remodeling inhaler form and orally as a controller [5]. Studies [1, 2]. The pathogenesis of airway remodeling has not in vitro have shown that β2 selective-agonists exert anti- been fully elucidated. It may be a consequence of airway inflammatory activity. β2 selective-agonists increase cyclic inflammation [3, 4]. β2 adrenergic agonists are not only AMP levels, which inhibit mast cell and eosinophil de- granulation, apoptosis and cytokine production [6–9]. * Correspondence: [email protected] Procaterol can also reduce the expression of adhesion 2Department of Immunology, Mie University Graduate School of Medicine, molecules [6, 10]. A previous study has shown that sys- Edobashi 2-174, Tsu, Mie 514-8507, Japan β Full list of author information is available at the end of the article temic administration of tulobuterol, a 2-selective agonist, © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Kainuma et al. Respiratory Research (2017) 18:79 Page 2 of 11 decreases eosinophil adhesion to endothelial cells resulting Preparation of human eosinophils in reduction of eosinophil inflammation [11]. β2 adrener- Eosinophils from healthy human volunteers (age 30 to gic agonists are also very effective bronchodilators in 45 years old with no present history of any disease) were COPD and they are part of the therapeutic strategy for the purified by negative selection using anti-CD16 and anti- management of COPD patients [12, 13]. Short acting or CD14 bound micromagnetic beads as previously described long acting β2 agonists are administered in clinical practice [19]. The purity of eosinophils was more than 97% as mea- through inhaler devices whose delivery efficiency has sured by the Randoph’s phloxine-methylene blue stain [21]. substantially improved by the use of computational models [13–17]. Co-culture experiment and morphological analysis Epithelial to mesenchymal transition (EMT) leads to BEAS-2B cells were cultured in 6- or 12-well plates until increased number of myofibroblasts in cancer and fibrotic 60–70% cell confluence, then serum-starved for 24 h. diseases [18]. Eosinophils can cause airway remodeling by Eosinophils were pre-treated with procaterol (provided − promoting EMT [19]. Recently, we and others have re- by Otsuka Pharmacy) at 10 9 Mfor1h.Humaneosino- ported that direct contact of eosinophils with bronchial phils (1 × 106 cells for 12-well plate, 2 × 106 cells for 6-well epithelial cells increases the expression of TGF-β1 leading plate) were added to the culture RPMI medium and incu- to induction of EMT [20]. In the present study, we hy- bated for further 24 h. After co-culture, human eosinophils pothesized that procaterol can suppress EMT of airway were removed from adherent BEAS-2B cells by gentle pip- epithelial cells induced by eosinophils. etting. BEAS-2B cells were stained by Diff-Quick technique and photographed for analyzing morphological changes. Methods For immunofluorescence, cells were fixed with 4% parafor- Reagent maldehyde for 10 min at room temperature and stained L-glutamine, penicillin/streptomycin, donkey anti-mouse with mouse anti-E-cadherin mAb and anti α-SMA Ab IgG-Alexa Fluor 488, Chicken anti-rabbit IgG-Alexa (rabbit polyclonal) followed by the secondary antibodies Fluor 594, Laemmli sample buffer and Trizol Reagent (donkey anti-mouse IgG conjugated with AF488 and chi- were purchased from Invitrogen (Carlsbad, CA). Dulbec- ken anti-rabbit IgG conjugated with AF594. Deparaffinized co’s modified Eagle’s medium (DMEM), RPMI-1640 and tissue sections were subjected to hydrated autoclaving for bovine serum albumin (BSA) were from Sigma (St Louis, antigen retrieval. After washing with Tris-buffered saline, MO), and fetal bovine serum (FBS) from Thermo scien- slides were exposed to mouse anti–human E-cadherin anti- tific. Rabbit anti α-SMA, anti-CD16 and anti-CD14 bound body (1:200) overnight at 4 °C and subsequently incubated micromagnetic beads were purchased from Miltenyi Bio- with donkey anti-mouse IgG-Alexa Fluor 488 (1:200) for tec (Auburn, CA), mouse anti-human E-cadherin antibody 4 h at room temperature after washing. Staining of α-SMA from BD Biosciences (Mississauga, ON, Canada), and was done using rabbit anti–human α-SMA antibody anti-TGF-β1 monoclonal antibody (mAb) (1D11) from (1:200) and then chicken anti-rabbit IgG-Alexa Fluor 594 R&D Systems (Minneapolis, MN). Sepasol-RNA I super G (1:200). After washing, the sections were counterstained (Nacalai tesque), anti-mouse antibodies against CD11b with 4,6-diamidino-2-phenylindole (DAPI) and mounted (integrin αM), CD49d (integrin α4), CD29 (integrin β1), using a fluorescence mounting medium. 5 CD18 (integrin β1), CD54 (ICAM-1), and CD106 In separate experiments, human eosinophils (2 × 10 − (VCAM-1) were from BioLegend. cells) were prepared and treated with 10 7 M procaterol − or 10 5 M forskolin (Nacalai Tesque, Kyoto, Japan) for Cell lines 30 min at 37 °C. A group of eosinophils was then co- BEAS-2B, an adenovirus 12-SV40 virus hybrid (Ad12SV40) cultured with serum-starved semi-confluent BEAS-2B transformed human epithelial cells, was obtained from the cells (2.5 × 105 cells/well, 12-well plate) for 24 h and the Riken Cell Bank (Tsukuba, Japan), and cultured in DMEM cell surface expression of integrins on eosinophils was supplemented with 10% (v/v) heat-inactivated FBS, 0.03% evaluated by flow cytometry. Control eosinophils were (w/v) L-glutamine, 100 IU/ml penicillin and 100 μg/ml cultured alone for 24 h. Another group of eosinophils streptomycin. EoL-1 cells were obtained from the Riken was co-cultured with BEAS-2B cells for 48 h and the cell Cell Bank, maintained in suspension culture at 37 °C and supernatants and adherent cells (BEAS-2B cells) were 5%CO2 in humidified atmosphere using RPMI-1640 collected for analysis of cytokine expression by RT-PCR medium supplemented with 10%(v/v) heat-inactivated FBS, and immunoassays. 0.03%(w/v) L-glutamine, 100 IU/ml penicillin and 100 μg/ ml streptomycin. For differentiation, EoL-1 cells were di- Reverse transcriptase polymerase chain reaction (RT-PCR) luted to 5 × 105 cells/ml and 0.5 mM sodium n-butyrate After co-culture of BEAS-2B cells and eosinophils for (BA) was added. EoL-1 cells were incubated with 0.5 mM 24 h, eosinophils were removed as described above. BA for 5 days. Total RNA was extracted from BEAS-2B cells by the Kainuma et al. Respiratory Research (2017) 18:79 Page 3 of 11 guanidine isothiocyanate procedure using Trizol Reagent. out at 72 °C for 5 min. The PCR products were sepa- RNA was reverse-transcribed using oligo-dT primers and rated on a 2% agarose gel containing 0.01% ethidium then the DNA was amplified by PCR. The sequences of bromide. The RNA concentration and purity were deter- the primers are as follows: for human vimentin, forward mined by UV absorption at 260:280 using an Ultrrospec 5′-GAGAACTTTGCCGTTGAAGC-3′ and reverse 5′- 1100 pro UV/Vis spectrophotometer (Amersham Biosci- GCTTCCTGTAGGTGGTGGCAATC-3′;forhuman ences, NJ). The amount of mRNA was normalized against E-cadherin forward: 5′-GTATCTTCCCCGCCCTGCC the GAPDH mRNA.
Recommended publications
  • Ep 2626065 A1
    (19) TZZ Z_T (11) EP 2 626 065 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: A61K 31/137 (2006.01) A61K 31/135 (2006.01) 14.08.2013 Bulletin 2013/33 A61K 31/4704 (2006.01) A61K 31/58 (2006.01) A61K 31/56 (2006.01) A61K 9/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11827927.2 A61K 9/14 A61P 11/06 (86) International application number: Date of filing: 01.02.2011 (22) PCT/CN2011/070883 (87) International publication number: WO 2012/041031 (05.04.2012 Gazette 2012/14) (84) Designated Contracting States: (72) Inventor: WU, Wei-hsiu AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Taiwan (TW) PL PT RO RS SE SI SK SM TR (74) Representative: Patentanwaltskanzlei WILHELM (30) Priority: 28.09.2010 CN 201010502339 & BECK Prinzenstrasse 13 (71) Applicant: Intech Biopharm Ltd. 80639 München (DE) Taipei (TW) (54) COMPOUND COMPOSITION FOR INHALATION USED FOR TREATING ASTHMA (57) An inhaled pharmaceutical composition con- tric way as a controller. The eccentric way control therapy tains primary active ingredients of beta2- agonist and cor- could create a low blood concentration period during the ticosteroids.The pharmaceuticalcompositions disclosed day and minimize the acute tolerance phenomenon (or in the present invention are to be inhaled by a patient so called tachyphylaxis) for bronchodilator - beta2-ago- when needed as a reliever, or administrated in an eccen- nists in treating asthma or other obstructive respiratory disorders.
    [Show full text]
  • Clenbuterol Elisa Kit Instructions Product #101219 & 101216 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology CLENBUTEROL ELISA KIT INSTRUCTIONS PRODUCT #101219 & 101216 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Clenbuterol and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Clenbuterol ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug- enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • Emea/666243/2009
    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients
    Journal of Clinical Medicine Review Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients Yoshiaki Minakata * and Seigo Sasaki Department of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Wakayama 644-0044, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-738-22-3256 Received: 7 September 2020; Accepted: 27 October 2020; Published: 29 October 2020 Abstract: Increasing physical activity (PA) in patients with chronic obstructive pulmonary disease (COPD) is an important issue, however, the effect of bronchodilators on PA is still controversial. The indicators of PA, as measured by an accelerometer, can easily fluctuate based on several factors, which might cause inconsistent results. In this review, we listed the indicators of PA and the factors influencing the reproducibility of indicators of PA, and reviewed reports in which the effects of bronchodilators on PA were evaluated by an accelerometer. Then, we investigated the association between the processing of influencing factors and the effectiveness of bronchodilators for improving the PA of COPD patients. Fifteen reports were extracted using the PubMed database. In all seven reports in which adjustment was performed for at least two of four influencing factors (non-wear time, data from days with special behavior, environmental factors, and number of valid days required to obtain reproducible data), bronchodilators showed beneficial effects on PA. No adjustment was made for any of these factors in any of the four bronchodilator-ineffective reports. This suggests that the processing of influencing factors to secure reproducibility might affect the results regarding the effectiveness of bronchodilators for improving PA in COPD patients.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0047336A1 Yang Et Al
    US 20090047336A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0047336A1 Yang et al. (43) Pub. Date: Feb. 19, 2009 (54) NOVEL FORMULATION OF DEHYDRATED Publication Classification LPID VESICLES FOR CONTROLLED (51) Int. Cl. RELEASE OF ACTIVE PHARMACEUTICAL A63/37 (2006.01) INGREDIENT VLANHALATION A6II 47/06 (2006.01) A 6LX 9/27 (2006.01) (75) Inventors: Zhijun Yang, Kowloon (CN); A6IR 9/14 (2006.01) Wenhua Huang, Kowloon (CN); A6IP II/00 (2006.01) Chi Sun Wong, Hong Kong (CN); A6IP II/06 (2006.01) Zhongzhen Zhao, Kowloon (CN) (52) U.S. Cl. .......... 424/450; 424/489: 514/653: 514/772 Correspondence Address: (57) ABSTRACT LEYDIG VOIT & MAYER, LTD A new formulation of dehydrated lipid vesicles employs a 700 THIRTEENTH ST. NW, SUITE 300 vesicle preserver and permits the control of release and deliv WASHINGTON, DC 20005-3960 (US) ery of active pharmaceutical ingredients into the respiratory system for treatment in particular of asthma. The typical (73) Assignee: HONG KONG BAPTIST formulation provides controlled release of the active pharma UNIVERSITY, Kowloon (CN) ceutical ingredient from 0% to 100% from 0 to 72 hours after inhalation, changes the systemic administration to topical (21) Appl. No.: 11/840,537 administration, allows prolonged therapeutic period for one administration, increased stability, with reduced dose, (22) Filed: Aug. 17, 2007 reduced systemic side effects, reduced toxicity. S Patent Application Publication US 2009/0047336A1 60 T. 50 40 30 20 O O Time (hours) --DOPC+1% gly cerin w8m DOTAP+1% glycerin FIG. 2 US 2009/0047336A1 Feb. 19, 2009 NOVEL FORMULATION OF DEHYDRATED blood pressure.
    [Show full text]
  • Dry Powder Inhalers Comprising a Carrier Other Than Lactose
    (19) TZZ Z T (11) EP 2 682 097 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.01.2014 Bulletin 2014/02 A61K 9/00 (2006.01) A61K 9/14 (2006.01) A61K 31/40 (2006.01) A61K 31/439 (2006.01) (2006.01) (21) Application number: 13175077.0 A61K 31/4704 (22) Date of filing: 04.07.2013 (84) Designated Contracting States: • Türkyilmaz, Ali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 34460 Istanbul (TR) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Mutlu, Onur PL PT RO RS SE SI SK SM TR 34460 Istanbul (TR) Designated Extension States: BA ME (74) Representative: Sevinç, Erkan Istanbul Patent & Trademark (30) Priority: 05.07.2012 TR 201207842 Consultancy Ltd. Plaza 33, Buyukdere Cad. No: 33/16 (71) Applicant: Arven Ilac Sanayi Ve Ticaret A.S. Sisli Istanbul 34460 (TR) 34381 Istanbul (TR) (72) Inventors: • Cifter, Ümit 34460 Istanbul (TR) (54) Dry Powder Inhalers Comprising A Carrier Other Than Lactose (57) This invention relates to novel pharmaceutical other obstructive airways diseases. In addition, the compositions for inhalation comprising separately, se- present invention relates to novel pharmaceutical com- quentially or together, drugs having amine in the form of position for inhalation based on combinations of long act- a dry powder in admixture with a pharmaceutically ac- ing muscarinic antagonists, long acting beta agonists, ceptable carrier, other than lactose, and its use in the short acting beta-2 agonists, corticosteroids or a combi- treatment of respiratory condition selected from asthma nation of two or more of them.
    [Show full text]
  • The Combination of Salbutamol Nebulizer and Oral Procaterol to the Indonesian Children with Pneumonia
    Iranian Journal of Pharmaceutical Sciences 2020: 16 (3): 59-72 www.ijps.ir Original Article The Combination of Salbutamol Nebulizer and Oral Procaterol to the Indonesian Children with Pneumonia Endang Darmawan*, Leny Kusumawati Department of Clinical Pharmacy, Faculty of Pharmacy, Ahmad Dahlan University, Yogyakarta, Indonesia. Abstract This study aimed to examine the effectiveness of combining salbutamol nebulizer and oral procaterol compared to only oral procaterol on the respiratory rate, temperature (fever), spasm, cough frequency, thoracic retraction, and length of stay (LOS) among young children with pneumonia. This prospective cohort study included 48 consecutive sampling subjects with pneumonia in Indonesia. The subjects were classified based on the type of therapy they received: intervention group used the combination of salbutamol nebulizer and oral procaterol therapy (n=24 subjects) and the control group received oral procaterol only (n=24). The result showed that the combination therapy salbutamol nebulizer and oral procaterol was more effective than the administration of oral procaterol only with the rate of clinical change. Combination therapy nebulized salbutamol and oral procaterol significantly respiratory rate (p=0.006) and temperature (fever) (p=0.002) compared to the only oral procaterol. The combination had clinical change in reducing spasm, cough frequency, thoracic retraction, and length of stay (LOS) however there are was no significant effect of this combination in reducing spasm (p=0.348), cough frequency (p=0.964), thoracic retraction (p=0.666), and length of stay (LOS) (p=0.192) compared to the only oral procaterol among the Indonesian children with pneumonia. Keywords: Children, Cough, Length of stay, Pneumonia, Procaterol, Salbutamol nebulizer.
    [Show full text]
  • Emerging Inhaled Bronchodilators: an Update
    Eur Respir J 2009; 34: 757–769 DOI: 10.1183/09031936.00013109 CopyrightßERS Journals Ltd 2009 REVIEW Emerging inhaled bronchodilators: an update M. Cazzola* and M.G. Matera# ABSTRACT: Bronchodilators remain central to the symptomatic management of chronic AFFILIATIONS obstructive pulmonary disease and asthma, and, for this reason and also because the patent *Unit of Respiratory Clinical Pharmacology, Dept of Internal protection of many bronchodilators has expired, several companies have reinitiated research into Medicine, University of Rome Tor the field. Vergata, Rome, and The only limits set for the development of a long-lasting bronchodilator with a new product #Unit of Pharmacology, Dept of profile are medical needs and marketing opportunities. The incorporation of once-daily dose Experimental Medicine, Second University of Naples, Naples, Italy. administration is an important strategy for improving adherence and is a regimen preferred by most patients. CORRESPONDENCE A variety of b2-agonists and antimuscarinic agents with longer half-lives and inhalers containing M. Cazzola a combination of several classes of long-acting bronchodilator are currently under development. Dipartimento di Medicina Interna Universita` di Roma ‘Tor Vergata’ The present article reviews all of the most important compounds under development, Via Montpellier 1 describing what has been done and discussing their genuine advantage. Rome 00133 Italy KEYWORDS: Bronchodilators, combination therapy, long-acting antimuscarinic agents, E-mail: [email protected]
    [Show full text]
  • WO 2017/042341 Al 16 March 2017 (16.03.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/042341 Al 16 March 2017 (16.03.2017) P O P C T (51) International Patent Classification: (74) Agents: MANFORD, Fergus et al; Vectura Limited, In A61K 9/14 (2006.01) B02C 19/06 (2006.01) tellectual Property Department, One Prospect West, Chip A61K 31/40 (2006.01) penham Wiltshire SN14 6FH (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP20 16/07 1321 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 9 September 2016 (09.09.2016) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 15 18455 1.8 9 September 2015 (09.09.2015) EP SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (71) Applicant: VECTURA LIMITED [GB/GB]; One Pro ZW.
    [Show full text]
  • Compositions of Glycopyrronium Salt for Inhalation
    (19) TZZ Z¥_T (11) EP 2 037 879 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/12 (2006.01) 15.05.2013 Bulletin 2013/20 A61K 9/14 (2006.01) A61K 31/40 (2006.01) (21) Application number: 07764925.9 (86) International application number: PCT/EP2007/005744 (22) Date of filing: 28.06.2007 (87) International publication number: WO 2008/000482 (03.01.2008 Gazette 2008/01) (54) COMPOSITIONS OF GLYCOPYRRONIUM SALT FOR INHALATION FORMULIERUNGEN ENTHALTEND GLYCOPYRRONIUMSALZ ZUR INHALATION COMPOSITIONS À INHALER À BASE D’UN SEL DE GLYCOPYRRONIUM (84) Designated Contracting States: • WIRTH, Wolfgang AT BE BG CH CY CZ DE DK EE ES FI FR GB GR CH-4422 Arisdorf (CH) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • BAUMBERGER, Anton SI SK TR CH-4102 Binningen (CH) • ABEL, Stephan (30) Priority: 30.06.2006 GB 0613161 79576 Weil am Rhein (DE) • KAERGER, Sebastian (43) Date of publication of application: D-07407 Rudolstadt (CH) 25.03.2009 Bulletin 2009/13 • KIECKBUSCH, Thomas 79539 Lörrach (DE) (73) Proprietor: Novartis AG 4056 Basel (CH) (74) Representative: McLean, Craig Sutherland Novartis Pharma AG (72) Inventors: Patent Department • HAEBERLIN, Barbara 4002 Basel (CH) CH-4142 Münchenstein (CH) • STOWASSER, Frank (56) References cited: 79730 Murg (DE) WO-A-01/76575 WO-A-2005/105043 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • ASTHMA + TUE HISTORICAL PERSPECTIVE: Asthma + TUE
    ASTHMA + TUE HISTORICAL PERSPECTIVE: Asthma + TUE <2004 WADA: abbreviated TUE for β2 agonist use 2004 WADA: Objective proof of AHR required for TUE for inhaled β2 agonist use (salbutamol, salmeterol, formoterol, terbutaline) 2010 WADA: Removal of TUE requirement for salbutamol (urinary thresholds) and salmeterol / 2 HISTORICAL PERSPECTIVE: Asthma + TUE < 2011: Declaration of Use for inhaled GC 2011: Declaration of Use no longer required for inhaled GC 2013: Formoterol: TUE only for doses > 54 mcg/d / 3 2014: one can still get a TUE for the prohibited β2 agonists if TUE criteria are fulfilled Prohibited Substances ASTHMA TUE • All oral/ intravenous β2 agonists REQUIREMENTS • All oral/ intravenous GC • Salbutamol (>1600mcg/ d) or (> 1000ng/mL in urine) • Formoterol (> 54 mcg over 24h) • Terbutaline • Procaterol + other LABA • **Salmeterol does not need a TUE!** / 5 Medical File to Support TUE Application ASTHMA TUE • Medical History REQUIREMENTS • Clinical Examination • Spirometry report, or • Bronchial Provocation Test • Treating Physician contact info. • Explanation as to why salbutamol, salmeterol or formoterol are not appropriate / 6 Objective criteria for granting of a TUE for β2 agonists Objective Test Criteria to be met for permission to use β2 agonists Spirometry Bronchodilator test ≥12% increase in FEV1 over baseline following inhalation of an inhaled beta 2 agonist Objective Test Criteria to be met for permission to use β2 agonists Bronchial Provocation Tests Eucapnic Voluntary Hyperpnea ≥10% fall of FEV1 Methacholine Aerosol challenge
    [Show full text]